News

Pfizer fails in late-stage trial for sickle cell disease therapy

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

Pfizer's sickle-cell treatment efforts falter as drug fails study

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...
mlive on MSN3d

‘Potential exposure’ at Portage Pfizer plant sends people to hospital, MIOSHA investigating

Several workers reported symptoms of being exposed to a substance and some were taken to the hospital. The state is ...

Pfizer's combination therapy improves survival in bladder cancer trial

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer: This Is What Bulls Waited For

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Pfizer's sickle cell drug fails late-stage trial

Pfizer's experimental drug to treat sickle cell anemia failed to meet the main goal in a late stage trial, the drugmaker said ...

Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again?

Pfizer ( PFE -0.18%) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID ...